Pharmaceutical Raw Materials

This product is used in the pharmaceutical industry. Sodium pantothenate is a prescription drug suitable for the long-term replacement treatment of congenital hypothyroidism (cretinism) and hypothyroidism caused by various causes in children and adults.

Phenoxymethylpenicillin is a narrow spectrum antibiotic also commonly referred to as Penicillin V or Penicillin VK. It is a phenoxymethyl analog of Penicillin G, or [benzylpenicillin]. An orally active naturally penicillin, phenoxymethylpenicillin is used to treat mild to moderate infections in the respiratory tract, skin, and soft tissues caused by penicillin G­-sensitive microorganisms. Phenoxymethylpenicillin has also be used in some cases as prophylaxis against susceptible organisms. While there have been no controlled clinical efficacy studies that were conducted, phenoxymethylpenicillin has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract, except for those who are at an elevated risk for endocarditis.

This product can be used as intermediate of medicine, pesticide, dye and surfactant.

This product is used as medicine raw material.

Nevirapine is a non nucleoside reverse transcriptase inhibitor, which blocks RNA dependent and DNA dependent DNA polymerase activity by directly connecting with HIV-1 reverse transcriptase (RT) and breaking the catalytic end of the enzyme. It does not compete with substrate or nucleoside triphosphate, and can be combined with other antiretroviral drugs to treat HIV-1 infection. In June 1996, it was approved by the U.S. Food and Drug Administration (FDA) to treat adult HIV infection with nucleoside drugs. At present, common adverse reactions include skin rash, abnormal liver function, fatigue, fever, headache, drowsiness, gastrointestinal adverse reactions and myalgia. Severe liver injury, liver failure and allergic reaction. In January 2005, FDA released a message on its official website to remind medical staff that patients with high CD4 cell count (male > 400 / mm3, female > 250 / mm3) have a higher risk of liver injury. Therefore, for patients who have not received antiviral therapy before, if the CD4 cell count is higher than the above two limits, nevirapine should be avoided.